The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.

Independent · Updated weekly · 114 compounds

The Compound Report

The research database for peptides, compounds, and longevity interventions.

Browse all compounds·How we grade evidence·Reconstitution calculator

Featured compounds

Hand-picked starting points — the most-asked-about chapters.

Featured
C

GHK-Cu

The Body's Own Repair Signal — And the Evidence Gap Between What It Does and How People Use It

TopicalGray-market onlyView
Featured
C

BPC-157

544 Papers, 30 Years, One Lab — The Healing Peptide with the Most Research and the Least Independent Evidence

InjectableGray-market onlyView
Featured
C

Semaglutide

The Only FDA-Approved Drug in This Book. The Most Prescribed Drug in Human History. STEP Program: -14.9% Body Weight at 68 Weeks. SELECT Trial: 20% Reduction in Major Cardiovascular Events. Grade A Evidence Across the Broadest Human Trial Program of Any Compound in This Book. The Weight Rebound Question: 2/3 of Weight Returns Within 1 Year of Stopping in Controlled Trials. The Compounded Semaglutide Regulatory Crisis. What the Real-World Data Actually Shows About Discontinuation.

InjectableFDA-approvedView

Browse by goal

114 compounds across 12 categories.

6 compounds

Longevity & Anti-aging

Compounds that target hallmarks of aging.

RapamycinNAD+/NMNEpithalon
3 FDA-approved · 2 research chemical
3 compounds

Muscle & Performance

Growth hormone secretagogues, IGF analogs, SARMs.

IGF-LR3CJC-1295+IpamorelinTesamorelin
2 FDA-approved · 1 research chemical
2 compounds

Weight Loss & Metabolic

GLP-1, GIP, glucagon receptor agonists and metabolic modulators.

SemaglutideTirzepatideRetatrutide
2 FDA-approved
2 compounds

Mitochondrial & Energy

Mitochondrial-targeted peptides and cofactors.

NAD+/NMNMOTS-cSS-31
1 research chemical · 1 other
1 compound

Sleep & Recovery

Compounds that improve sleep architecture or circadian timing.

DSIPPinealonEpithalon
1 research chemical
1 compound

Libido & Sexual Health

Melanocortin agonists, gonadotropic peptides.

PT-141Melanotan IIKisspeptin-10
1 FDA-approved

Popular stacks

Community-defined protocols — graded for the combination, not the sum of the parts.

StackMuscleSleep

GH Stack

C
Animal replicated

CJC-1295 + Ipamorelin — the synergistic growth hormone pulse

CJC-1295 + Ipamorelin
0human trials25animal
1 compounds · Growth hormone optimization: body composition, sleep, recovery
View
StackHealingSkin,

GLOW Stack

C
Animal replicated

The cosmetic repair triple — skin, hair, and healing combined

GHK-CuBPC-157TB-500
0human trials50animal
3 compounds · Cosmetic tissue remodeling combined with soft-tissue repair
View
StackGutHealing

Gut Stack

D
In vitro / mechanistic

BPC-157 + KPV — structural repair meets anti-inflammatory signaling

BPC-157KPV
0human trials30animal
2 compounds · Gut healing, intestinal permeability, IBD-adjacent conditions
View
StackHealing

Wolverine Stack

C
Animal replicated

The canonical injury-recovery combination

BPC-157TB-500
0human trials40animal
2 compounds · Accelerated soft-tissue and musculoskeletal healing
View

Latest research

Updated weekly. 60 entries from the current corpus.

NewsTirzepatide· 2026-05-15 · 1 week ago

SURPASS-CVOT cardiovascular outcomes trial expected to read out Q3 2026 — will define cardiovascular benefit relative to dulaglutide active comparator.

New studyTirzepatide· 2026-03-08 · 2 months ago

SYNERGY-NASH publishes: tirzepatide produced MASH resolution in 62% of patients at 52 weeks at top dose, with measurable fibrosis improvement.

New studyDOISLU-PP-332· 2026-01-01 · 4 months ago
An orally active estrogen receptor–related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity — Journal of Pharmacology and Experimental Therapeutics
New studyDOISLU-PP-332· 2026-01-01 · 4 months ago
Analysis and Identification of In Vitro Metabolites of Exercise Mimetic SLU-PP-332 ERRα/β/γ Agonist for Doping-Control Purposes — Drug Testing and Analysis
New studyDOITirzepatide· 2026-01-01 · 4 months ago
Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal — JAMA Internal Medicine
New studyARA-290· 2026-01-01 · 4 months ago

Prohibited List S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics — ARA-290/cibinetide covered as EPO-related substance activating EPO receptor complex

New studyBPC-157· 2026-01-01 · 4 months ago

Prohibited List — S0 Non-Approved Substances; S2 Peptide Hormones, Growth Factors — BPC-157 prohibited at all times since 2022

New studyCardarine· 2026-01-01 · 4 months ago

What Should Tested Athletes Know About GW1516? [Supplement contamination risk documented; S4 — 4 ban confirmed; zero tolerance policy]

New studyCJC-1295 + Ipamorelin· 2026-01-01 · 4 months ago

CJC-1295 — Developmental Drug Classification; nominated for 503A Category 2 withdrawn April 22, 2026 — Ongoing FDA scrutiny under developmental drug framework

New studyCJC-1295 + Ipamorelin· 2026-01-01 · 4 months ago

Prohibited List S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics — S2

Items derive from the most recent citations on each compound chapter until the live aggregator ships.

We document peer-reviewed science and community reality in parallel — visibly distinct, never blended.

How we work